目的:评价电脑肝病治疗仪治疗病毒性肝炎的疗效及不良反应。方法:将116例病毒性肝炎患者随机分为治疗组及对照组,治疗组60例,对照组56例。两组均以抗炎、保肝、降酶、退黄、对症为治则。治疗组加用电脑肝病仪治疗，每日一次。结果:治疗组在消化道症状改善方面有效率950%,黄疸消退方面有效率902%。谷丙转氨酶恢复方面有效率85%。而对照组分别为8214%、6786%和7143%。结论:电脑肝病治疗仪治疗肝病能迅速改善消化道症状,有效降低黄疸、转氨酶,未见明显不良反应。
Objective To observe the eotaxin expression of rat airway smooth muscle cells ( ASMCs) induced by serum from asthmatic rats, and explore the possible mechanism. Methods ASMCs isolated fromrat tracheas were cultured in vivo. Then they were treated with serum from asthmatic rats, or treated with serum and dexamethasone simultaneously. The level of eotaxin protein in supernatant and eotaxin mRNA in ASMCs were measured by ELISA and reverse transcription-polymerase chain reaction. The expression of cAMP in ASMCs was examined by radioimmunoassay. Results After the treatment with sensitized serum, the eotaxin level in supernatant and mRNA expression in ASMCs were significantly higher [ ( 107. 09 ±7. 12) ng/L vs. ( 0. 63 ±0. 56) ng/L, P lt; 0. 05; 1. 39 ±0. 04 vs. 0. 05 ±0. 01, P lt;0. 05] , and the level of cAMP in ASMCs was significantly lower compared with the control group [ ( 17. 58 ±3. 62) ng/L vs. ( 32. 39 ±3. 36) ng/L, P lt; 0. 05] . After intervened by the sensitized serum and dexamethasone simultaneously, the protein and mRNA expressions of eotaxin were lower compared with those intervened by sensitized serumalone [ ( 64. 18 ±4. 04) ng/L and 0. 77 ±0. 19] . The level of eotaxin in supernatant was negatively correlated with cAMP level in ASMCs ( r = - 0. 788, P lt; 0. 01) . Conclusions There is anautocrine function in ASMCs as inflammatory cells after stimulation with sensitized serum. Eotaxin may play an important roll in the pathogenesis of asthma via a cAMP-dependent pathway.
目的 观察茵陈柴平汤治疗重度慢性乙型肝炎的疗效及不良反应。 方法 2009年3月－2010年3月，选择采用茵陈柴平汤联合常规保肝药物治疗50例重度慢性乙型肝炎患者（治疗组），并与50例仅用常规保肝药物治疗的重度慢性乙型肝炎患者（对照组）进行比较，观察治疗2、4周时的临床症状、肝功能及凝血酶原活动度等指标的变化。 结果 治疗2、4周时，治疗组在肝功能及凝血酶原活动度等指标均有显著改善，无严重不良反应；4周时，治疗组的症状缓解率（84%）明显高于对照组（66%）；其总有效率（96%）亦高于对照组（80%）。 结论 茵陈柴平汤治疗重度慢性乙型肝炎具有较好的临床疗效，且无严重不良反应。
ObjectiveTo understand the role of metformin on reducing incidence of type 2 diabetes mellitus (T2MD) patients complicated with liver cancer. MethodThe related literatures of metformin treated patients with T2MD complicated with liver cancer at home and abroad in recent years were reviewed. ResultsA large number of epidemiological and clinical data showed that the metformin might prevent the occurrence of the T2MD patients complicated with liver cancer, its mechanism was mainly inhibited the proliferation of hepatoma cells through the ATM-LKB1-AMPK-mTOR pathway, PI3K/Akt/mTOR pathway, or miRNA. The current controversy was the authenticity of the data, the influencing factors included the aging problem and characteristics of metformin user. The prospective study design rigorous remained to be clarified. ConclusionMetformin could reduce the incidence of T2MD patients complicated with liver cancer, and could inhibit the growth of liver cancer cells, which provides a new way of thinking for the comprehensive treatment of liver cancer.
Objective To investigate the strategy of treatment and prevention of hemorrhage after radical resection of hilar cholangiocarcinoma. Method Reviewing the related literatures at home and abroad in recent years, to summarize the progress of treatment and prevention of hemorrhage after radical resection of hilar cholangiocarcinoma. Results We should clear the postoperative bleeding time, extent, cause, and location, to help the clinician to choose the appropriate timing of intervention and treatment. The patients with early hemorrhage and mild degree hemorrhage could be treated conservatively. If patients with severe hemorrhage and hemodynamic disorders, surgical intervention must be decisive. Patients with late hemorrhage would have serious consequences, and these patients should receive interventional or surgical treatment as early as possible. Conclusions For patients with hilar cholangiocarcinoma after radical resection, doctors need to do accurate preoperative evaluation, meticulous operation, and intensive management after operation, to reduce the incidence of hemorrhage after radical resection of hilar cholangiocarcinoma. If the postoperative hemorrhage occurs, the cause, location, time, and degree of hemorrhage should be clearly defined to facilitate clinicians to make rapid clinical decisions and to develop treatment programs.
目的 探讨后路手术中360°植骨融合术治疗腰椎滑脱症的近期疗效。 方法 2008年1月－2011年2月收治39例腰椎滑脱症患者，男21例，女18例；年龄35～75岁，平均51岁。病程12～50个月，平均31个月。滑脱部位：腰3 1例，腰4 11例，腰5 24例，腰4、5 3例。腰椎退变性滑脱27例，峡部裂性滑脱12例。按Meyerding分度：Ⅰ度21例，Ⅱ度13例，Ⅲ度5例。患者均有腰腿痛症状，保守治疗无效后行后路减压、复位及椎弓根钉棒系统内固定，术中以360°行椎间及后外侧三维立体植骨融合，在椎体前中柱采用植骨加椎间融合器的融合方式。术后定期随访，摄X线片检测融合情况，使用视觉模拟疼痛（VAS）评分评估症状缓解情况，Greenough-Fraser综合评分评价腰腿痛治疗结果。 结果 有36例患者获随访，随访时间12～36个月，平均24个月。植骨愈合率100%，愈合时间10～18个月，平均14个月。无内固定松动、断裂、外露及脱落等并发症发生。术前下肢神经根痛VAS评分为（7.52 ± 1.23）分，末次随访时为（1.67 ± 1.18）分；下腰痛术前（6.83 ± 1.51）分，末次随访时为（1.11 ±0.76）分；手术前后比较差异均有统计学意义（P＜0.05）。Greenough-Fraser综合评分术前为（24 ± 7）分，末次随访时为（55 ± 4）分，差异有统计学意义（P＜0.05）。 结论 360°植骨融合术治疗腰椎滑脱症是一种确实有效的融合方法，利于提高相应区域的植骨融合率及恢复椎间隙高度，使融合更稳定。